Protocol No.: GS-US-595-6184

A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Principal Investigator
Kurian, Sobha
Phase
III
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Emily Hawkins, BSN
Research Nurse
Phone: +1 304-293-7375

View on ClinicalTrials.gov